Every 424B that LONGEVITY HEALTH HLDGS (XAGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow XAGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAGE filings page.
Longevity Health Holdings, Inc. filed a prospectus supplement relating to 44,382 shares of common stock registered under an existing Form S-1 and updated the disclosure by incorporating a new current report. The company’s common stock trades on the OTC marketplace under the symbol XAGE, with a last reported sale price of $0.222 per share on August 14, 2026. The incorporated Form 8-K describes a settlement with Puritan Partners LLC of litigation dating back to November 2023, which had constrained access to capital and strategic opportunities. Under a Settlement Agreement, Longevity exchanged an existing note and warrant for new 10% senior secured convertible notes with an aggregate principal amount of $2,350,000 maturing in February 2028, and the parties will file a stipulation dismissing the action without prejudice. The company highlights risks related to these financing instruments, including potential dilution, security interests in substantially all company and specified subsidiary assets, and repayment and default-related obligations.
Longevity Health Holdings, Inc. filed a prospectus supplement covering 44,382 shares of common stock and updating its S-1 prospectus with the attached Quarterly Report for the period ended June 30, 2026. The company operates a single-segment bio-aesthetics business focused on cosmetic skincare and haircare in the United States.
For the first six months of 2026, net sales were $787,755, down from $1,013,965 in 2025 as demand softened amid increased competition and heavier promotions. Gross profit was $472,561, while the company recorded a net loss of $3,315,003. Operating expenses declined materially to $2,525,203 from $3,937,836 due to lower legal, compensation, R&D and marketing spending.
Liquidity remains highly constrained. As of June 30, 2026, cash and cash equivalents were $35,471, net working capital was negative $8,881,397, and stockholders’ deficit was $8,699,447. Management disclosed substantial doubt about the ability to continue as a going concern and is relying on additional financing and potential acquisitions of cash-generating assets. Subsequent to quarter end, the company entered into a settlement with Puritan Partners LLC, issuing new $2,350,000 senior secured convertible notes maturing in 2028.
Longevity Health Holdings filed a prospectus supplement covering 44,382 shares of common stock and attaching a current report describing a financing-linked litigation settlement. The company and subsidiary Carmell Regen entered a Settlement Agreement with Puritan Partners that resolves a New York action and replaces prior instruments with two new senior secured convertible notes.
Longevity issued a $1,250,000 Initial Note and a $1,100,000 Additional Note, each bearing 10% annual interest and maturing on February 13, 2028. The notes are convertible at $0.50 per share or, at Puritan’s option, at 80% of the five-day average closing price when the stock trades below that level. They are guaranteed by key subsidiaries and secured by a first-priority lien on substantially all assets, including intellectual property, and carry default remedies such as a 115% redemption premium and 15% default interest plus a confession of judgment mechanism.
The company must use 25% of gross proceeds from specified future financings to offer prepayment of the notes and has agreed to reserve at least four times the maximum shares needed for conversion and to file a resale registration within 30 days. Director Scott Frisch resigned from the board on August 11, 2026, stating his decision did not arise from any disagreement with the company.
Longevity Health Holdings, Inc. filed a prospectus supplement registering 44,382 shares of Common Stock as part of its amended Form S-1 prospectus; the supplement incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. The supplement states common stock trades on the OTC under the symbol XAGE and discloses 2,475,321 shares outstanding as of May 13, 2026. The attached Form 10-Q shows $313,396 in cash, a net loss of $(1,431,713) for the three months ended March 31, 2026, and management’s statement that conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Longevity Health Holdings, Inc. files a prospectus supplement registering 44,382 shares of Common Stock as an amendment to its Form S-1 prospectus dated June 5, 2024. The supplement incorporates the Company’s Form 10-K for the fiscal year ended December 31, 2025 and attaches an 8-K.
The Company trades on the OTC market under symbol XAGE; the last reported sale price was $0.39 per share on March 30, 2026. The Form 10-K discloses a closed PIPE on March 16, 2026 raising $200,000 from the sale of 689,656 shares at $0.29 per share, a CEO transition with severance payments of $30,000 per month for 12 months (with conditional extension), and management’s conclusion that substantial doubt exists about the Company’s ability to continue as a going concern.